Penpulimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | PD-1 |
| Clinical data | |
| Other names | AK105, penpulimab-kcqx |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic agent |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| IUPHAR/BPS | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6434H9922N1718O2012S46 |
| Molar mass | 145008.92 g·mol−1 |
Penpulimab is a humanized monoclonal antibody used for the treatment of cancer. It targets the programmed cell death protein 1 (PD-1) receptor.
Penpulimab was approved for medical use in China in August 2021, and in the United States in April 2025.